EXAS - イグザクト・サイエンシズ (Exact Sciences Corporation) イグザクト・サイエンシズ



symbol EXAS
会社名 EXACT Sciences Corp. (イグザクト・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イグザクト・サイエンシズ(Exact Sciences Corporation)は分子診断会社である。同社は癌の早期発見および予防に焦点を当てている。同社は結腸直腸癌および前癌の早期発見のためのCologuardと呼ばれる非侵襲的スクリーニング試験を提供する。コングルード試験はデオキシリボ核酸(DNA)および結腸直腸癌および前癌に関連するヘモグロビンバイオマーカーを検出するための多標的アプローチを利用する便ベースのデオキシリボ核酸(sDNA)スクリーニング試験である。コルグアード試験は、結腸直腸新生物に関連するDNAマーカーの定性的検出およびヒトの便における潜在性ヘモグロビンの存在を目的としている。同社は他のタイプの癌に対する追加試験の開発に焦点を当てる。同社はコンピュータ断層撮影(CT)または他のスキャンによって発見された肺結節を有する個体において、肺癌の早期発見を助けるための血液ベースのバイオマーカー試験を開発している。   イグザクト・サイエンシズは米国の癌検出製品メ―カ―。大腸癌および前癌状態の早期発見と予防に焦点を当て、非侵襲性スクリ―ニングテスト製品を開発。排便からDNAを検出し大腸癌に関わる遺伝子から癌を見つけ出す製品「Cologuard」を提供。同製品は前癌病変やポリ―プ、および大腸癌の4段階の進行度を検出する。   A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
本社所在地 441 Charmany Drive Madison WI 53719 USA
代表者氏名 Kevin T. Conroy ケヴィン・T・コンローイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 608-284-5700
設立年月日 34731
市場名 NASDAQ Small Cap
ipoyear 2001年
従業員数 1268人
url www.exactsciences.com
nasdaq_url https://www.nasdaq.com/symbol/exas
EBITDA EBITDA(百万ドル) -102.08500
終値(lastsale) 68.46
時価総額(marketcap) 8403727817.94
時価総額 時価総額(百万ドル) 8597.679
売上高 売上高(百万ドル) 353.17000
企業価値(EV) 企業価値(EV)(百万ドル) 828.906
当期純利益 当期純利益(百万ドル) -249.37200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 EXACT Sciences Corporation revenues increased 82% to $193.2M. Net loss applicable to common stockholders increased 15% to $75.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 38% to $55.1M (expense) Interest expense increase from $104K to $15.1M (expense).



   Exact Sciences Corporation (NASDAQ:EXAS) Has Recovered 10.28% So Far, But Another -306.19% Loss Cannot Be Ruled Out  2022/07/01 13:30:00 Marketing Sentinel
In last trading session, Exact Sciences Corporation (NASDAQ:EXAS) saw 1.74 million shares changing hands with its beta currently measuring 1.27. Company’s recent per share price level of $39.39 trading at -$1.19 or -2.93% at ring of the bell on the day assigns it a market valuation of $6.48B. That closing price of EXAS’s stock is … Exact Sciences Corporation (NASDAQ:EXAS) Has Recovered 10.28% So Far, But Another -306.19% Loss Cannot Be Ruled Out Read More »
   Exact Sciences Corp. Shares Close the Week 20.1% Lower - Weekly Wrap  2022/06/17 00:00:00 Kwhen Finance
Exact Sciences Corp. (EXAS) shares closed this week 20.1% lower than it did at the end of last week. The stock is currently down 54.2% year-to-date, down 70.4% over the past 12 months, and up 10.4% over the past five years. This week, the Dow Jones Industrial Average fell 7.2%, and the S&P 500 fell 8.7%. Trading Activity Shares traded as high as $43.44 and as low as $35.34 this week.Shares closed 72.4% below its 52-week high and 4.8% above its 52-week low.Trading volume this week was 8.7% lower than the 10-day average and 8.5% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 48.1% The company's stock price performance over the past 12 months lags the peer average by 61.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   5 Cathie Wood Stocks to Buy in June  2022/06/09 15:00:28 InvestorPlace
Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve raises borrowing costs.” Investors have been keeping away from riskier technology stocks in favor of established industries that deliver steady profits. As a result, Wood’s flagship ARK Innovation ETF (NYSEARCA: ARKK ) has fallen 50% year-to-date (YTD), whereas the S&P 500 and the NASDAQ 100 indices have only declined 11.9% and 17.4%, respectively. The recent rout in technology stocks is undeniably significant. But if history is any guide, these declines will also be temporary. Innovation will continue to be a primary driving force of the modern economy. Accordingly, our readers might want to capitalize on the current selloff to invest in tech innovators at discount prices. 7 Top-Rated Large-Cap Stocks to Buy and Hold With that information, here are the five best Cathie Wood Stocks to buy in June: Ticker Company Price EXAS Exact Sciences Corporation $47.71 IONS Ionis Pharmaceuticals, Inc. $34.74 KTOS Kratos Defense & Security Solutions, Inc. $14.69 TRMB Trimble Inc. $66.57 PATH UiPath Inc. $21.12 Cathie Wood Stocks to Buy: Exact Sciences (EXAS) Source: Tada Images / Shutterstock 52-week range: $45.25 – $133.99 Biotech group Exact Sciences (NASDAQ: EXAS ) focuses on the early detection and treatment guidance for cancer.
   Expert Ratings for Exact Sciences  2022/06/03 13:08:30 Benzinga
Exact Sciences (NASDAQ: EXAS ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Exact Sciences. The company has an average price target of $81.0 with a high of $95.00 and a low of $50.00. Below is a summary of how these 5 analysts rated Exact Sciences over the past 3 … Full story available on Benzinga.com
   Exact Sciences to participate in June investor conferences  2022/05/27 10:00:00 PR Newswire
MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair 42nd Annual Growth…
   Exact Sciences to participate in J.P. Morgan Healthcare Conference  2022/01/03 11:00:00 Kwhen Finance
   Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Banque Cantonale Vaudoise  2021/12/23 10:08:42 ETF Daily News
Banque Cantonale Vaudoise increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 14.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,275 shares of the medical research company’s stock after acquiring an additional 555 shares during the quarter. […] The post Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Banque Cantonale Vaudoise appeared first on ETF Daily News .
   Wright Investors Service Inc. Buys New Shares in Exact Sciences Co. (NASDAQ:EXAS)  2021/12/22 13:18:43 Dakota Financial News
Wright Investors Service Inc. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,950 shares of the medical research companys stock, valued at approximately $758,000. Several other hedge funds and other institutional []
   Voya VARIABLE PRODUCTS TRUST Buys Avalara Inc, Bio-Techne Corp, Roku Inc, Sells Spotify ...  2021/12/19 11:38:02 GuruFocus
   Wanger Advisors Trust Buys Bill.com Holdings Inc, Avalara Inc, Etsy Inc, Sells Teradyne Inc, ...  2021/12/19 02:38:03 GuruFocus
Related Stocks: AMED , PLNT , VRM , BILL , AVLR , ETSY , RBLX , ALGN , EXAS , TER , MASI , CHE , ZNGA , WSO , NTRA ,
   Exact Sciences slumps after insider sale; Evercore ISI says it is an overreaction  2021/08/03 17:54:05 Seeking Alpha
   Exact Sciences Corp (EXAS) CFO Jeffrey Thomas Elliott Sold $4.3 million of Shares  2021/08/03 03:15:09 GuruFocus
Related Stocks: EXAS ,
   Breast Cancer Screening Market Growing Popularity and Number of Medical Services to Propel Global Industry | Oncocyte Corporation, POC Medical Systems, Exact Sciences Corporation, Danaher  2021/08/02 13:53:06 OpenPR
According to The Insight Partners market research study titled '' Breast cancer screening Market Forecast to 2027 Covid-19 Impact and Global Analysis by Test Type and End User. The major players operating in the Breast Cancer Screening Market include Koninklijke
   Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com  2021/08/01 06:56:05 Investing.com
Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.
   Analyst Valuation and EPS Growth NASDAQ:FSFG, NASDAQ:EXAS, NYSE:BUD, NYSE:GFF  2021/08/01 06:08:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post Analyst Valuation and EPS Growth NASDAQ:FSFG, NASDAQ:EXAS, NYSE:BUD, NYSE:GFF appeared first on .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イグザクト・サイエンシズ EXAS Exact Sciences Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)